替莫唑胺治疗复发性恶性脑胶质瘤临床观察

Clinical Study of Temozolomide for Recurrent Malignant Glioma

目的观察替莫唑胺治疗复发性脑胶质瘤的疗效及安全性。方法32例复发的恶性胶质瘤患者给予替莫唑胺100～200mg/m2,连服5d,28为一周期。所有患者至少接受两个疗程治疗。替莫唑胺化疗后,对32例患者进行脑MRI复查,根据MRI结果判断疗效。结果中位无进展生存期为5.9个月。6例患者的肿瘤明显缩小,PR率为18.75%;11例患者肿瘤稳定,SD率为34.38%。14例患者无进展生存期超过6个月(43.75%)。替莫唑胺主要不良反应为恶心、呕吐、脱发、疲倦和骨髓抑制等,程度较轻,未见重要脏器损害。结论替莫唑胺对恶性复发性胶质瘤仍有一定的临床效果且不良反应轻,是理想的治疗用药。

Objective To evaluate the efficacy and side effects of temozolomide in the treatment of recurrent malignant gliomas.Methods Total 32 patients with recurrent malignant gliomas were treated by temozolomide with a dosage of 100～200mg/m^2 once a day for durative 5 days and 28 days was a treatment cycle.All the patients received at least two cycles of the treatment and were confirmed by the MRI examination after chemotherapy.Results The partial response （PR） rate was 18.75% （6/32）,stable disease（SD） rate was 34.38%（11/32）,14 patients（43.75%） showed a progression-free survival time more than 6 months.The major toxicity of temozolomide included nausea,vomiting,baldness,anergy and leukopenia.No severe side effect was found in these patients.Conclusion Temozolomide is an effective and tolerable regimen for refractory malignant gliomas with low incidence of adverse effects.